Core Viewpoint - A securities class action lawsuit has been filed against Zynex, Inc. following its bankruptcy and allegations of a significant overbilling scheme targeting government payors [2][3] Summary of Allegations - The lawsuit alleges that Zynex engaged in a systematic "oversupplying" scheme, shipping excessive medical supplies to inflate billings, with some patients receiving up to 128 electrode pairs per month regardless of medical necessity [5] - Zynex's management is accused of failing to disclose the severity of issues related to overbilling and lacked effective internal controls to prevent manipulation of supply orders and billing data [5] - The company faced a suspension of payments from its largest payor, Tricare, in early 2025, which was concealed by management until a settlement of over $85 million was agreed upon to resolve fraud allegations [5] - Following these revelations, Zynex filed for Chapter 11 bankruptcy and was delisted from the Nasdaq, resulting in significant losses for common equity holders [5] Legal Proceedings - The class action lawsuit, titled Beidel v. Sandgaard, et al., was filed in the U.S. District Court for the District of Colorado, seeking to recover losses for investors who purchased Zynex securities between February 25, 2021, and December 15, 2025 [2][4] - A critical deadline for investors to apply as Lead Plaintiff is set for April 21, 2026 [4] Management Indictments - Former CEO Thomas Sandgaard and former COO Anna Lucsok were indicted for health care and securities fraud on January 21, 2026, leading to their removal from the company [5]

Core Viewpoint - A securities class action lawsuit has been filed against Zynex, Inc. and its former executives following the company's bankruptcy and allegations of a significant overbilling scheme [2][3]. Summary of Allegations - The lawsuit alleges that Zynex engaged in a systematic "oversupplying" scheme, shipping excessive medical supplies to inflate billings to government and private payors, with some patients receiving up to 128 electrode pairs per month [5]. - The complaint claims that Zynex lacked effective internal controls to prevent manipulation of supply orders and billing data [5]. - Zynex's largest payor, Tricare, suspended payments in early 2025, and management allegedly concealed the severity of this suspension until the company had to forfeit over $85 million to resolve fraud allegations [5]. - Former CEO Thomas Sandgaard and former COO Anna Lucsok were indicted for health care and securities fraud on January 21, 2026, leading to their removal from the company [5]. - Following these revelations, Zynex filed for Chapter 11 bankruptcy and was delisted from the Nasdaq, resulting in significant losses for common equity holders [5]. Legal Proceedings - The class action lawsuit, titled Beidel v. Sandgaard, et al., seeks to recover losses for all individuals and entities that purchased Zynex securities from February 25, 2021, to December 15, 2025 [2][4]. - Investors have until April 21, 2026, to request to be appointed as Lead Plaintiff in the case [4].

Core Insights - McKesson Corporation (MCK) is valued at a market cap of $101.7 billion and operates in healthcare services and information technology, focusing on the distribution of pharmaceuticals and medical supplies, as well as offering healthcare IT solutions [1] Financial Performance - Analysts expect MCK to report a profit of $9.19 per share for fiscal Q3 2026, representing a 14.5% increase from $8.03 per share in the same quarter last year [2] - For fiscal 2026, MCK is projected to report a profit of $38.61 per share, up 16.8% from $33.05 per share in fiscal 2025, with further growth expected to $43.53 per share in fiscal 2027, a year-over-year increase of 12.7% [3] Stock Performance - MCK shares have increased by 38% over the past 52 weeks, significantly outperforming the S&P 500 Index's 17% return and the State Street Health Care Select Sector SPDR ETF's 12.6% increase during the same period [4] - Following the release of impressive Q2 results, MCK's shares surged by 1.7% in the subsequent trading session, with overall revenue rising 10.1% year-over-year to $103.2 billion and adjusted EPS increasing by 39.5% from the previous year [5] Analyst Ratings - Wall Street analysts maintain a highly optimistic outlook on MCK's stock, with a "Strong Buy" rating from 13 out of 17 analysts, while four analysts suggest a "Hold" rating. The mean price target for MCK is $940.94, indicating a potential upside of 15.5% from current levels [6]

Group 1 - Cardinal Health, Inc. (NYSE:CAH) is recognized as one of the 20 Best Performing Dividend Stocks in 2025, indicating strong market performance and investor confidence [1] - The company has shifted its focus towards higher-margin areas such as specialty pharmaceuticals and managed services, resulting in significant earnings growth, with forecasts estimating a growth of 19.3% in FY 2026 and 12.6% in FY 2027 [2] - The current payout ratio for dividends is at a modest 30.6%, providing the company with flexibility to potentially increase returns to shareholders in the future [3] Group 2 - Cardinal Health has raised its fiscal 2026 outlook, now expecting adjusted earnings per share between $9.65 and $9.85, an increase from the previous range of $9.30 to $9.50, reflecting a strong first-quarter performance [4] - The forecast includes contributions from the pending acquisition of Solaris Health, expected to close in early November, which may further enhance the company's growth prospects [4] - Cardinal Health operates as a global healthcare company, involved in the distribution of pharmaceuticals and medical products, manufacturing medical supplies, and providing various healthcare services [5]

Core Insights - Medline's IPO debuted at $29 per share, raising approximately $6.26 billion with an implied valuation near $50 billion, marking it as the largest listing of the year [1] - The company is backed by major investment firms including Blackstone, Carlyle, and Hellman & Friedman, and increased its offering to meet strong institutional demand [1] Financial Performance - Medline carries about $17 billion in debt from a 2021 leveraged buyout and plans to use IPO proceeds to repay senior secured term loans, which is viewed positively by credit rating agencies [3] - For the nine months ending September 2025, Medline reported approximately $1 billion in net income on $20.6 billion in revenue, with adjusted EBITDA of $2.7 billion and a margin of 13.3% [4] - Analysts suggest that if Medline allocates $3–$4 billion for debt repayment, it could reduce leverage ratios by 0.5–1.0x, which is significant but not transformative [4] Customer Relationships and Market Position - The company boasts a 98% Prime Vendor retention rate, indicating strong customer relationships that support consistent cash generation [5] - Medline sources one-third of its products in-house from 33 manufacturing facilities, while the remainder comes from over 500 suppliers across 40 countries [7] Tariff Challenges and Competitive Landscape - Medline faces tariff headwinds that could impact earnings before taxes by $325–$375 million in 2025 and an additional $150–$200 million in 2026, which may offset organic growth [6] - The company must decide whether to absorb tariff costs or pass them on to hospitals, with most healthcare distributors only able to pass through 40–50% of these costs [8] - The competitive landscape includes major players like Cardinal Health, McKesson, and Owens & Minor, which intensifies pricing pressures due to private-label penetration and customer consolidation [8] Future Outlook - Investors are advised to monitor the company's ability to achieve a net leverage target of 2.5–3.0x within 18–24 months, as interest coverage and debt levels will be closely scrutinized [5] - The success of the IPO will depend on effective execution in deleveraging, managing tariff impacts, and maintaining margin discipline [9]

Core Insights - Cardinal Health, Inc. is a significant player in the healthcare services and products sector, with a market capitalization of $47.04 billion, focusing on the distribution of pharmaceuticals and medical supplies [1] Stock Performance - Cardinal Health's shares reached a 52-week high of $214.93 on November 26 but have since declined by 7.9% from that peak [2] - The stock has experienced a 31.2% increase over the past three months, outperforming the Nasdaq Composite index, which gained 7.8% during the same period [2] - Over the past 52 weeks, Cardinal Health's stock has gained 62.9%, and 28.9% over the past six months, while the Nasdaq Composite gained 19.5% and 20.3%, respectively [3] Financial Performance - For the first quarter of fiscal 2026, Cardinal Health reported revenues of $64.01 billion, a 22% year-over-year increase, surpassing Wall Street's expectation of $59.05 billion [4] - The company's non-GAAP EPS rose by 36% year-over-year to $2.55, exceeding the analysts' estimate of $2.21 [4] - Cardinal Health raised its fiscal 2026 non-GAAP EPS outlook from a range of $9.30-$9.50 to $9.65-$9.85, indicating projected growth of 17%-20% [5] Strategic Developments - The stock rose 15.4% intraday on October 30 following the strong quarterly results and updated outlook [5] - Cardinal Health completed the acquisition of urology MSO Solaris Health, adding over 750 providers to its multi-specialty MSO platform [5] Competitive Positioning - Compared to Cencora, Inc., which gained 40.2% over the past 52 weeks and 18.8% over the past six months, Cardinal Health has demonstrated superior performance [6]

Core Insights - McKesson Corporation, based in Irving, Texas, is one of America's oldest businesses with a market capitalization of approximately $105.6 billion, focusing on pharmaceutical distribution, medical supply delivery, and technology solutions [1] Market Performance - Over the past 52 weeks, McKesson's stock has increased by 39.8% and by 51% year-to-date, significantly outperforming the S&P 500 Index, which gained 12.3% and 12.5% in the same periods [2] - The stock has also outperformed the S&P 500 Healthcare Sector SPDR, which saw a 7.5% increase over the past 52 weeks and a 10.9% rise year-to-date [3] Financial Results - For the second quarter of fiscal year 2026, McKesson reported a revenue increase of 10.1% year-over-year, reaching $103.2 billion, aligning with analyst expectations, driven by stronger prescription volumes and broader distribution of oncology and multispecialty products [4] - Earnings per share (EPS) surged 377% annually to $8.92, surpassing expectations, and the management has raised its adjusted EPS outlook for fiscal year 2026 to a range of $38.35 to $38.85 [5] Analyst Outlook - Analysts forecast a 17% EPS growth to $38.66 on a diluted basis for the fiscal year ending in March 2026, with McKesson exceeding analyst expectations for three consecutive quarters [6] - The consensus rating among 16 analysts covering McKesson is "Strong Buy," with 13 "Strong Buy" calls and three "Hold" recommendations [6] - Following the Q2 results, Baird analyst Eric Coldwell raised McKesson's price target to $927 from $873, maintaining an "Outperform" stance, indicating confidence in the company's momentum [7]

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was $2.7 billion, up 1.5% compared to the prior year [25] - Adjusted net income for Q4 was $43 million or $0.55 per share, compared to $54 million or $0.69 per share last year [31] - Adjusted EBITDA was $138 million, down from $170 million reported in Q4 2023 [32] - Gross profit in Q4 was $580 million, representing 21.5% of net revenue [28] Business Line Data and Key Metrics Changes - Patient Direct revenue grew by 5% in Q4 2024, with strong growth in sleep supplies and diabetes [27] - The Products and Health Care Services (P&HS) segment grew 0.5% overall in Q4, with same-store sales growth in medical distribution offset by lower glove pricing [26][20] - Adjusted operating income was $95 million in Q4, an increase compared to the third quarter but lower than the previous year [30] Market Data and Key Metrics Changes - The IV fluid shortage impacted procedure volume and sales volume to distribution customers [26] - Home respiratory therapies such as NIV and oxygen declined year-over-year, but there are expectations for a return to growth in 2025 [28] Company Strategy and Development Direction - The company is focused on optimizing its P&HS segment and leveraging its Patient Direct platform for growth [9] - Plans to acquire Rotech are underway, with expectations to close in the first half of 2025, aiming to drive long-term shareholder value [10][14] - A share repurchase program of up to $100 million has been authorized by the Board of Directors [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the future of the Patient Direct business, citing positive demographic trends and expanding home treatment options [9] - The company anticipates mid-single-digit revenue growth for 2025, primarily driven by the Patient Direct segment [35] - Management remains focused on reducing debt and maintaining a debt-to-EBITDA leverage ratio between two and three times [38] Other Important Information - The company repaid $647 million of debt over the last two years, demonstrating strong cash flow capabilities [10][33] - A goodwill impairment charge of $305 million was recorded in Q4, primarily due to adverse financial market changes [32] Q&A Session Summary Question: Concerns about Rotech's performance - Management indicated there were no surprises in Rotech's results, consistent with expectations despite external legislative impacts [46][47] Question: Free cash flow and share repurchase strategy - The primary objective is to pay down debt, but share repurchase will be considered opportunistically if the stock remains undervalued [50] Question: Trends in Patient Direct growth - Management noted strong growth in diabetes and sleep supplies, with plans to improve performance in home respiratory categories [57][58] Question: Impact of tariffs - Tariffs are not significantly impacting the company, as most products are not sourced from high-tariff regions [72][74] Question: Capitated contract impact - The large capitated contract is not expected to have a meaningful impact on 2025 results, as current pricing is already modeled into projections [104][105] Question: Growth expectations for P&HS and Patient Direct - The majority of revenue growth is expected to come from the Patient Direct segment, with modest improvements in margins across both segments [111]